Is GRCE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GRCE. It does not provide personalized investment advice.

GRCE (Grace Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Grace Therapeutics, Inc. Common Stock (GRCE) is a publicly traded Healthcare sector company. As of September 18, 2026, GRCE trades at $2.11 with a market cap of $44.81M and a P/E ratio of -4.54. GRCE moved -0.94% today. Year to date, GRCE is -42.35%; over the trailing twelve months it is -32.37%. Its 52-week range spans $1.75 to $5.18. Analyst consensus is moderatebuy with an average price target of $4.00. Rallies surfaces GRCE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are GRCE's key financials?

GRCE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GRCE recently traded at $2.11. Market cap is $44.81M. P/E ratio is -4.54. Revenue is $0.

GRCE Key Metrics

Key financial metrics for GRCE
Metric	Value
Price	$2.11
Market Cap	$44.81M
P/E Ratio	-4.54
EPS	$-0.47
Dividend Yield	0.00%
52-Week High	$5.18
52-Week Low	$1.75
Volume	68.00K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-7.79M
Gross Margin	0.00%

GRCE Analyst Consensus

1 analysts cover GRCE: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $4.00.

Common questions about GRCE

What are GRCE's key financials?: GRCE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GRCE recently traded at $2.11. Market cap is $44.81M. P/E ratio is -4.54. Revenue is $0.
Is GRCE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GRCE. It does not provide personalized investment advice.